RMI venture fund is currently managed by RMI Partners, a venture capital company focused on breakthrough developments of pharmaceutical products and technologies.
RMI was created in March 2012. Initial funding - $380 million. The investor of RMI is RUSNANO, the nanotechnology investment, research and development arm of the Russian Government.
NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.
24 May 2017
23 May 2017